Literature DB >> 30497106

Liver resection for recurrent hepatocellular carcinoma after radiofrequency ablation therapy.

Shunsuke Yamagishi1, Yutaka Midorikawa1, Hisashi Nakayama1, Tokio Higaki1, Masamichi Moriguchi1, Osamu Aramaki1, Shintaro Yamazaki1, Shingo Tsuji2, Tadatoshi Takayama1.   

Abstract

AIM: Although radiofrequency ablation (RFA) is an effective local treatment of hepatocellular carcinoma (HCC), local recurrence is relatively frequent. We aimed to elucidate the validity of salvage liver resection for recurrent HCC after RFA.
METHODS: Patients who underwent liver resection for recurrent HCC after RFA (LR after RFA) and those who underwent second liver resection for recurrent HCC (second LR) were included. The short-term outcomes were compared between the two groups. The survival rates between the two groups were compared after propensity-score matching to adjust for the variables, including patient background, liver function, and tumor status.
RESULTS: Major resection was frequently carried out in the LR after RFA group, but there was no significant difference both in operative data and complication rate between LR after RFA (n = 54) and second LR (n = 266) groups. After a median follow-up period of 1.8 years (range, 0.2-10.5), the median overall survival was 4.4 years (95% confidence interval [CI], 2.2 - not applicable) and 5.6 years (95% CI, 4.5-7.3; P = 0.023) in the LR after RFA group (n = 54) and second LR group (n = 54), respectively, and recurrence-free survival was 1.3 years (0.4-2.2) and 1.2 years (0.5-1.8, P = 0.469), respectively. The only independent factor for overall survival of the LR after RFA group was local recurrence (hazard ratio, 2.73; 1.06-9.00).
CONCLUSIONS: Salvage liver resection of recurrent HCC after RFA could be recommended due to the safety of the procedure, especially in patients without local tumor progression after RFA.
© 2018 The Japan Society of Hepatology.

Entities:  

Keywords:  radiofrequency ablation; recurrent hepatocellular carcinoma; salvage liver resection

Year:  2019        PMID: 30497106     DOI: 10.1111/hepr.13293

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  3 in total

1.  Liver Resection Versus Embolization for Recurrent Hepatocellular Carcinoma.

Authors:  Yutaka Midorikawa; Tadatoshi Takayama; Masamichi Moriguchi; Rempei Yagi; Shunsuke Yamagishi; Hisashi Nakayama; Osamu Aramaki; Shintaro Yamazaki; Shingo Tsuji; Tokio Higaki
Journal:  World J Surg       Date:  2020-01       Impact factor: 3.352

2.  Follow-up schedule for initial recurrent hepatocellular carcinoma after ablation based on risk classification.

Authors:  Xuqi Sun; Lingling Li; Ning Lyu; Luwen Mu; Jinfa Lai; Ming Zhao
Journal:  Cancer Imaging       Date:  2020-07-01       Impact factor: 3.909

Review 3.  Recurrent Hepatocellular Carcinoma: Patterns, Detection, Staging and Treatment.

Authors:  Dimitrios Papaconstantinou; Diamantis I Tsilimigras; Timothy M Pawlik
Journal:  J Hepatocell Carcinoma       Date:  2022-09-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.